18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE

Published on Sep 1, 2020in Practical radiation oncology2.948
· DOI :10.1016/J.PRRO.2020.05.007
Abhishek A. Solanki11
Estimated H-index: 11
(LUC: Loyola University Chicago),
Bital Savir-Baruch13
Estimated H-index: 13
(LUC: Loyola University Chicago)
+ 41 AuthorsJian Q. Yu27
Estimated H-index: 27
Sources
Abstract
Purpose Conventional imaging rarely localizes the site(s) of prostate cancer recurrence in patients undergoing evaluation for salvage radiotherapy (sRT) after radical prostatectomy (RP). XXX (NCTXXX) was a prospective multicenter study investigating the impact of 18F-fluciclovine positron emission tomography/computed tomography (PET/CT) on the management of patients with biochemical recurrence of prostate cancer after curative-intent radiation or RP and negative or equivocal conventional imaging. Our objective was to determine the impact of 18F-fluciclovine PET/CT on treatment decisions for men planning to undergo sRT for biochemical recurrence post-RP. Methods We conducted a subgroup analysis of post-RP patients enrolled in XXX who were planning to undergo sRT with or without hormonal therapy based on pre-scan documentation. 18F-Fluciclovine PET/CT was performed according to standardized procedures. The treatment plan post-scan was compared with the pre-scan plan and the Fisher Exact test used to determine the impact of pre-scan PSA and Gleason sum (GS) on positivity and anatomic patterns of uptake. Results A total of 114 patients (median pre-scan PSA 0.42 [interquartile range: 0.3–1.1] ng/mL) met selection criteria (54% of patients in XXX). Forty-eight (42%) had 18F-fluciclovine-avid lesions. Twelve patients (11%) had positive findings only in the prostate bed, 24 (21%) had positivity only in the pelvis (prostate bed or pelvic nodes), and 24 (21%) had extrapelvic findings. PSA >0.5 ng/mL and GS ≥8 were associated with a higher risk of extrapelvic positivity (p Post-scan, 55 (48%) patients had a management change; 37 (32%) had a change in overall treatment approach (i.e. omission of sRT) and 18 (16%) had sRT target modification. Conclusions 18F-Fluciclovine PET/CT is positive in nearly half of patients planning to undergo post-RP sRT with negative/equivocal conventional imaging, with findings frequently leading to changes in management. PSA >0.5 ng/mL and GS ≥8 are associated with a higher risk of extrapelvic positive findings.
📖 Papers frequently viewed together
21 Citations
3 Citations
149 Citations
References23
Newest
#1Andrew Scarsbrook (Leeds Teaching Hospitals NHS Trust)H-Index: 29
#2David Bottomley (Leeds Teaching Hospitals NHS Trust)H-Index: 20
Last. Fergus V. Gleeson (University of Oxford)H-Index: 58
view all 18 authors...
Abstract Purpose Early and accurate localisation of lesions in patients with biochemical recurrence (BCR) of prostate cancer may guide salvage therapy decisions. The present study, XXX, aimed to evaluate the impact of 18F-fluciclovine on management of men with BCR of prostate cancer. Methods Men with a first episode of BCR following curative-intent primary therapy were enrolled at 6 UK sites. Patients underwent 18F-fluciclovine PET/CT according to standardised procedures. Clinicians documented m...
21 CitationsSource
#1Birgit Pernthaler (Medical University of Graz)H-Index: 1
#2Roman KulnikH-Index: 3
Last. Herbert KvaternikH-Index: 6
view all 6 authors...
PurposeOne of the major challenges for all imaging modalities is accurate detection of prostate cancer (PCa) recurrence. Beyond the established 68Ga-PSMA, a novel promising PET tracer in PCa imaging is 18F-fluciclovine. For evaluating the advantages and disadvantages and the comparability, we conduc
38 CitationsSource
#1Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
#2Francesco Ceci (UNITO: University of Turin)H-Index: 24
Last. Johannes Czernin (UCLA: University of California, Los Angeles)H-Index: 94
view all 22 authors...
Summary Background National Comprehensive Cancer Network guidelines consider 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical prostatectomy, whereas European Association of Urology guidelines recommend prostate-specific membrane antigen (PSMA) PET-CT. To the best of our knowledge, no prospective head-to-head comparison between these tests has been done so far. The aim of this study was to compare prospectively paired 18F-fluciclovine and PSMA PET-CT s...
149 CitationsSource
#1Bital Savir-Baruch (Loyola University Medical Center)H-Index: 13
#2Petra Lovrec (Loyola University Medical Center)H-Index: 2
Last. David M. Schuster (Emory University)H-Index: 33
view all 7 authors...
OBJECTIVE. The purpose of this study is to show the performance and evaluate the factors influencing the positivity rate (PR) of commercially produced 18F-fluciclovine PET/CT in the detection of re...
13 CitationsSource
#1Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 97
#2Lale Kostakoglu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 56
Last. Barry A. Siegel (WashU: Washington University in St. Louis)H-Index: 103
view all 8 authors...
Purpose:The prospective, multicenter LOCATE (18F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with 18F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent.Materials and Methods:Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were su...
61 CitationsSource
#1Alan Pollack (UM: University of Miami)H-Index: 83
#2Theodore KarrisonH-Index: 88
Last. H.M. Sandler (Cedars-Sinai Medical Center)H-Index: 14
view all 19 authors...
89 CitationsSource
#1Phuoc T. TranH-Index: 50
#2Noura RadwanH-Index: 5
Last. M. A. EisenbergerH-Index: 4
view all 20 authors...
9 CitationsSource
#1Piet OstH-Index: 41
#2Dries ReyndersH-Index: 9
Last. Gert De MeerleerH-Index: 36
view all 18 authors...
PurposeRetrospective studies suggest that metastasis-directed therapy (MDT) for oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to assess the benefit of MDT in a randomized phase II trial.Patients and MethodsIn this multicenter, randomized, phase II study, patients with asymptomatic PCa were eligible if they had had a biochemical recurrence after primary PCa treatment with curative intent, three or fewer extracranial metastatic lesions on choline positron emissi...
487 CitationsSource
#1Matthew P. MillerH-Index: 6
#2Lale Kostakoglu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 56
Last. Penelope WardH-Index: 25
view all 9 authors...
: 18F-Fluciclovine is a novel PET/CT tracer. This blinded image evaluation (BIE) sought to demonstrate that, after limited training, readers naive to 18F-fluciclovine could interpret 18F-fluciclovine images from subjects with biochemically recurrent prostate cancer with acceptable diagnostic performance and reproducibility. The primary objectives were to establish individual readers' diagnostic performance and the overall interpretation (2/3 reader concordance) compared with standard-of-truth da...
31 CitationsSource
#1Tore Bach-Gansmo (Oslo University Hospital)H-Index: 9
#2Cristina NanniH-Index: 54
Last. Frode Willoch (University of Oslo)H-Index: 30
view all 16 authors...
Purpose: Sensitive detection of cancer foci in men experiencing biochemical recurrence following initial treatment of prostate cancer is of great clinical significance with a possible impact on subsequent treatment choice. We describe a multisite experience of the efficacy and safety of the positron emission tomography/computerized tomography agent fluciclovine (18F) after biochemical recurrence.Materials and Methods: A total of 596 patients underwent fluciclovine (18F) positron emission tomogra...
116 CitationsSource
Cited By5
Newest
#1Ali Salavati (Johns Hopkins University)H-Index: 1
#1Ali Salavati (Johns Hopkins University)H-Index: 1
Last. Jerry W. Froelich (UMN: University of Minnesota)H-Index: 26
view all 10 authors...
PURPOSE 18F-Fluciclovine PET imaging has been increasingly used in the restaging of prostate cancer patients with biochemical recurrence (BCR); however, its clinical utility in patients with low prostate-specific antigen (PSA) levels following primary radiation therapy has not been well-studied. This study aims to determine the detection rate and diagnostic accuracy of 18F-fluciclovine PET and the patterns of prostate cancer recurrence in patients with rising PSA after initial radiation therapy,...
Source
#1Soroush Rais-Bahrami (UAB: University of Alabama at Birmingham)H-Index: 48
#2Jason A. Efstathiou (Harvard University)H-Index: 55
Last. Andrew Scarsbrook (University of Leeds)H-Index: 9
view all 7 authors...
BACKGROUND A systematic literature review of the performance of 18Fluorine-fluciclovine PET/CT for imaging of men with recurrent prostate cancer was performed. METHODS Scientific literature databases (MEDLINE, ScienceDirect and Cochrane Libraries) were searched systematically during Oct 2020 using PRISMA criteria. No limit was put on the date of publication. Prospective studies reporting a patient-level 18F-fluciclovine detection rate (DR) from ≥25 patients with recurrent prostate cancer were so...
1 CitationsSource
#1Luca F. Valle (UCLA: University of California, Los Angeles)H-Index: 8
#1Luca F. Valle (UCLA: University of California, Los Angeles)H-Index: 3
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 9 authors...
Abstract Context The use, common findings, and impact of modern molecular positron emission tomography (PET)/computed tomography (CT) imaging prior to salvage radiation therapy (RT) in men with biochemical recurrence after radical prostatectomy (RP) have not been evaluated comprehensively. Objective We performed a scoping systematic review of the literature assessing detection rates, detection patterns, changes in management, as well as changes in patient outcome resulting from molecular PET/CT ...
4 CitationsSource
#1Bital Savir-Baruch (Loyola University Medical Center)H-Index: 13
#2Peter L. Choyke (NIH: National Institutes of Health)H-Index: 140
Last. Hossein Jadvar (SC: University of Southern California)H-Index: 40
view all 6 authors...
Twenty-five years ago, oligometastatic disease was proposed as an intermediary clinical state of cancer with unique implications for therapies that may impact cancer evolution and patient outcome. ...
1 CitationsSource
#1Olayinka A. Abiodun-Ojo (Emory University)H-Index: 4
#2Ashesh B. Jani (Emory University)H-Index: 35
Last. David M. Schuster (Emory University)H-Index: 33
view all 14 authors...
This study evaluated the impact of 18F-fluciclovine positron emission tomography/computed tomography (PET/CT) on salvage radiotherapy management decisions in patients with recurrent prostate cancer (PCa) post-prostatectomy. Methods: Patients with detectable prostate-specific antigen (PSA) post-prostatectomy were randomized to undergo either conventional imaging (CI) only (Arm A) or CI plus 18F-fluciclovine PET/CT (Arm B) prior to radiotherapy. In Arm B, positivity rates on CI and 18F-fluciclovin...
1 CitationsSource